Selective aldosterone antagonist

This page covers all Selective aldosterone antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mineralocorticoid receptor (MR).

Targets

Mineralocorticoid receptor (MR)

Marketed (2)

• Phase C: Eplerenone · National Institute of Cardiology, Warsaw, Poland · Cardiovascular
  Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.
• Eplerenone (Morning) · Vanderbilt University Medical Center · Cardiovascular
  Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.